Zoetis Inc. $ZTS Stake Increased by Swiss Life Asset Management Ltd

Swiss Life Asset Management Ltd lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 11.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 145,691 shares of the company’s stock after buying an additional 14,744 shares during the period. Swiss Life Asset Management Ltd’s holdings in Zoetis were worth $21,318,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC increased its stake in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis during the 3rd quarter worth $31,000. Financial Consulate Inc. bought a new position in Zoetis in the 3rd quarter valued at $39,000. SJS Investment Consulting Inc. increased its stake in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares during the period. Finally, TruNorth Capital Management LLC bought a new stake in shares of Zoetis during the third quarter worth $42,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS stock opened at $116.03 on Friday. The business has a 50 day moving average of $124.58 and a 200-day moving average of $130.88. The firm has a market cap of $48.98 billion, a PE ratio of 19.27, a P/E/G ratio of 1.79 and a beta of 0.95. Zoetis Inc. has a 12-month low of $114.47 and a 12-month high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the prior year, the firm earned $1.40 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. Barclays began coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. KeyCorp began coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Bank of America upped their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Finally, HSBC set a $140.00 price objective on Zoetis in a report on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Zoetis has an average rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.